ALEMBIC PHARMA share price has zoomed 4% and is presently trading at Rs 952.0.
Meanwhile, the BSE HEALTHCARE index is at 37,165.1 (down 0.2%).
Among the top gainers in the BSE HEALTHCARE index today are AARTI DRUGS (up 2.0%) and FDC (up 1.4%).
MAX HEALTHCARE INSTITUTE (down 2.6%) and METROPOLIS HEALTHCARE (down 1.6%) are among the top losers today.
Over the last one year, ALEMBIC PHARMA has moved up from Rs 640.8 to Rs 952.0, registering a gain of Rs 311.2 (up 48.6%).
On the other hand, the BSE HEALTHCARE index has moved up from 25,634.3 to 37,165.1, registering a gain of 45.0% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Glenmark Pharma (up 85.6%), Cadila Healthcare (up 83.8%) and CAPLIN POINT (up 82.8%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 79,419.7 (down 0.1%).
The top losers among the BSE Sensex today are Kotak Bank (down 1.4%) and Tata Motors (down 1.3%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 24,093.8 (down 0.2%). Kotak Bank and Bajaj Finance are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 63,915.4 to 79,419.7, registering a gain of 15,504.3 points (up 24.3%).
ALEMBIC PHARMA net profit grew 10.9% YoY to Rs 1,786 million for the quarter ended March 2024, compared to a profit of Rs 1,611 million a year ago. Net sales rose 7.9% to Rs 15,170 million during the period as against Rs 14,065 million in January-March 2023.
For the year ended March 2024, ALEMBIC PHARMA reported 80.1% increase in net profit to Rs 6,158 million compared to net profit of Rs 3,420 million during FY23. Revenue of the company grew 10.2% to Rs 62,286 million during FY24.
The current Price to earnings ratio of ALEMBIC PHARMA, based on rolling 12 month earnings, stands at 30.3.
Equitymaster requests your view! Post a comment on "ALEMBIC PHARMA Gains 4%; BSE HEALTHCARE Index Down 0.2%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!